Oslo  (Norway),  14 December  2021 -  PCI  Biotech (OSE: PCIB), a clinical-stage
biopharma  company developing  innovative therapeutics  that address significant
unmet  medical  needs  in  cancer  today  announced  that it has been invited to
present at the DNB Nordic Healthcare Conference 2021, an Oslo based online event
hosted by DNB.

On  Thursday, 16 December 2021 at 11:10 (CET), Dr. Per Walday, CEO, will present
an  overview  of  PCI  Biotech's  proprietary  platform technology via a general
company  presentation.  The  Company  is  also  available  for 1:1 meetings with
potential partners and investors.

The  presentation  slides  will  be  made  available  on  PCI  Biotech's website
(www.pcibiotech.com) under "Other presentations".

Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech
PCI  Biotech  is  a  biopharmaceutical  late-stage  clinical development company
focusing  on  development  and  commercialisation  of  novel  therapies  for the
treatment  of cancer through its  innovative photochemical internalisation (PCI)
technology  platform.  PCI  is  applied  to three distinct anticancer paradigms:
fimaChem  (enhancement of chemotherapeutics for  localised treatment of cancer),
fimaVacc  (T-cell induction technology for therapeutic vaccination), and fimaNAc
(nucleic acid therapeutics delivery).

Photochemical  internalisation induces triggered endosomal  release that is used
to  unlock the  true potential  of a  wide array  of therapeutic modalities. The
company's  lead programme fimaChem consists of  a pivotal study in perihilar and
distal bile duct cancer, an orphan indication with a high unmet need and without
approved  products.  fimaVacc  applies  a  unique  mode of action to enhance the
essential  cytotoxic  effect  of  therapeutic  cancer  vaccines,  which works in
synergy  with several  other state-of-the-art  vaccination technologies. fimaNAc
utilises  the  endosomal  release  to  provide intracellular delivery of nucleic
acids,  such as mRNA and RNAi therapeutics,  thereby addressing one of the major
bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements
This  announcement may contain forward-looking statements, which as such are not
historical  facts, but  are based  upon various  assumptions, many  of which are
based,  in  turn,  upon  further  assumptions.  These assumptions are inherently
subject  to  significant  known  and  unknown  risks,  uncertainties  and  other
important  factors. Such risks, uncertainties, contingencies and other important
factors  could cause  actual events  to differ  materially from the expectations
expressed  or implied in  this announcement by  such forward-looking statements.
PCI  Biotech disclaims  any obligation  to update  or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.